United Kingdom (UK)
Recombinant monoclonal antibody to Cathepsin B. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 2A2.
UniProt Accession Number of Target Protein: P07858
Alternative Name(s) of Target: Cat B; CTSB; CPSB; APPS; APP secretase; Cathepsin B1
Immunogen: The original antibody was generated by immunizing BALB/c mice with highly purified recombinant human cathepsin B expressed in E. coli.
Specificity: This antibody binds human cathepsin B (Cat B) at an epitope near the active site and inhibits its proteolytic activity. It was reported to specifically bind the 'EPGYSP' sequence located between amino acid residues 133–138 of cathepsin B. Cat B is a lysosomal cysteine protease that is shown to participate in processes of tumor growth, invasion, and metastasis. It is seen that the increased level of tumor cathepsin B is not balanced by an increase in cysteine proteases, leading to uncontrolled proteolysis in the extracellular matrix. Significantly increased levels of Cat B have also been found in sera of patients with breast, colorectal, liver, pancreatic, and melanoma cancers.
Application Notes: This antibody is capable of binding cathepsin B in an antigen-immobilized ELISA. The binding reactivity of this antibody to cathepsin B was also confirmed using Western blot. This antibody significantly inhibited the invasion of ras-transformed MCF-10A neoT cells through matrigel. This antibody was further reported to inhibit cathepsin B activity against BODYPY FL casein significantly (Fan et al., 2002; PMID: 12530548). In a study, the intracellular and extracellular cathepsin B activities in the invasion of ras-transformed human breast epithelial cells, MCF-10A neoT, were assessed using this antibody. This antibody was shown to impair both the intracellular and the extracellular fractions of cathepsin B activity (Premzl et al., 2003; PMID: 12581740). This antibody was also used in the generation of an ammodytoxin-anti-cathepsin B immuno-conjugate to deliver secretory phospholipase A2 into cancerous cells (Premzl et al., 2008; PMID: 18221975). This antibody was reported to potentiate cathepsin B exopeptidase activity with an activation constant (Ka) of 22.3 nm, although simultaneously inhibiting its endopeptidase activity (Mirković et al., 2009; PMID: 19656187).
Antibody first published in:
Fan et al. Molecular cloning and chimerisation of an inhibitory anti-cathepsin B antibody and its expression in Chinese hamster ovary cells. Biol Chem. 2002 Nov;383(11):1817-20. PMID:12530548
Note on publication:
The original article describes the cloning and generation of a chimeric antibody against cathepsin B in CHO cells.